CY1125052T1 - Κρυσταλλικες μορφες - Google Patents

Κρυσταλλικες μορφες

Info

Publication number
CY1125052T1
CY1125052T1 CY20221100195T CY221100195T CY1125052T1 CY 1125052 T1 CY1125052 T1 CY 1125052T1 CY 20221100195 T CY20221100195 T CY 20221100195T CY 221100195 T CY221100195 T CY 221100195T CY 1125052 T1 CY1125052 T1 CY 1125052T1
Authority
CY
Cyprus
Prior art keywords
crystal forms
pharmaceutical compositions
crystalline forms
crystalline
phosphono
Prior art date
Application number
CY20221100195T
Other languages
English (en)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CY1125052T1 publication Critical patent/CY1125052T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μια κρυσταλλική μορφή της ένωσης υδροχλωρικός βουτυλεστέρας του 4-((R)-2-{[6-((S)-3-μεθοξυ-πυρρολιδιν-1-υλ)-2-φαινυλο-πυριμιδινο-4-καρβονυλο]-αμινο}-3-φωσφονο-προπιονυλο)-πιπεραζινο-1-καρβοξυλικού οξέος, μεθόδους για την παρασκευή της, φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω κρυσταλλικές μορφές, φαρμακευτικές συνθέσεις που παρασκευάζονται από τέτοιες κρυσταλλικές μορφές και τη χρήση τους ως φάρμακο, ειδικά ως ένας ανταγωνιστής του υποδοχέα Ρ2Υ12.
CY20221100195T 2016-09-22 2022-03-09 Κρυσταλλικες μορφες CY1125052T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
CY1125052T1 true CY1125052T1 (el) 2024-02-16

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100195T CY1125052T1 (el) 2016-09-22 2022-03-09 Κρυσταλλικες μορφες

Country Status (28)

Country Link
US (3) US10730896B2 (el)
EP (2) EP3981774A1 (el)
JP (1) JP7097369B2 (el)
KR (1) KR102552795B1 (el)
CN (1) CN109715639B (el)
AU (1) AU2017331930B2 (el)
BR (1) BR112019004845A2 (el)
CA (1) CA3037794A1 (el)
CL (1) CL2019000728A1 (el)
CY (1) CY1125052T1 (el)
DK (1) DK3515924T3 (el)
EA (1) EA201990723A1 (el)
ES (1) ES2908572T3 (el)
HR (1) HRP20220234T1 (el)
HU (1) HUE057772T2 (el)
IL (1) IL265445B2 (el)
LT (1) LT3515924T (el)
MA (1) MA46266B1 (el)
MX (1) MX2019003093A (el)
MY (1) MY193080A (el)
PH (1) PH12019500567A1 (el)
PL (1) PL3515924T3 (el)
PT (1) PT3515924T (el)
RS (1) RS62946B1 (el)
SI (1) SI3515924T1 (el)
TW (1) TWI752086B (el)
UA (1) UA124073C2 (el)
WO (1) WO2018055016A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510043A (ja) 2017-03-15 2020-04-02 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd P2y12受容体アンタゴニストの皮下投与
CN115803012A (zh) 2020-07-15 2023-03-14 爱杜西亚药品有限公司 包含p2y12受体拮抗剂的水性医药组合物
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
MXPA05006302A (es) 2002-12-11 2005-08-29 Schering Ag Compuestos de 2-aminocarbonilquinolina como antagonistas de receptor de difosfato de adenosina plaquetario.
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AR057836A1 (es) 2005-10-21 2007-12-19 Actelion Pharmaceuticals Ltd Piperizinas como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
BRPI0810462A2 (pt) 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
US8518912B2 (en) * 2007-11-29 2013-08-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as P2Y12 receptor antagonists
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
BRPI1014039A2 (pt) 2009-04-08 2018-04-03 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas
US8664203B2 (en) 2009-04-22 2014-03-04 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as P2Y12 receptor antagonists
JP2020510043A (ja) 2017-03-15 2020-04-02 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd P2y12受容体アンタゴニストの皮下投与

Also Published As

Publication number Publication date
NZ750772A (en) 2023-10-27
ES2908572T3 (es) 2022-05-03
IL265445A (en) 2019-05-30
KR20190052704A (ko) 2019-05-16
EP3515924A1 (en) 2019-07-31
EA201990723A1 (ru) 2019-10-31
MA46266A (fr) 2019-07-31
US10730896B2 (en) 2020-08-04
IL265445B2 (en) 2024-05-01
IL265445B1 (en) 2024-01-01
RS62946B1 (sr) 2022-03-31
JP2019529553A (ja) 2019-10-17
BR112019004845A2 (pt) 2019-06-04
MA46266B1 (fr) 2022-02-28
CA3037794A1 (en) 2018-03-29
CN109715639A (zh) 2019-05-03
US20200017534A1 (en) 2020-01-16
UA124073C2 (uk) 2021-07-14
CN109715639B (zh) 2022-04-19
KR102552795B1 (ko) 2023-07-06
US11365209B2 (en) 2022-06-21
PL3515924T3 (pl) 2022-04-11
EP3515924B1 (en) 2021-12-15
EP3981774A1 (en) 2022-04-13
MX2019003093A (es) 2019-07-18
LT3515924T (lt) 2022-03-10
PT3515924T (pt) 2022-03-11
CL2019000728A1 (es) 2019-07-05
SI3515924T1 (sl) 2022-04-29
JP7097369B2 (ja) 2022-07-07
AU2017331930B2 (en) 2021-07-15
DK3515924T3 (da) 2022-03-21
US20210009614A1 (en) 2021-01-14
TW201813965A (zh) 2018-04-16
WO2018055016A1 (en) 2018-03-29
HUE057772T2 (hu) 2022-06-28
US20220275011A1 (en) 2022-09-01
HRP20220234T1 (hr) 2022-05-13
MY193080A (en) 2022-09-26
AU2017331930A1 (en) 2019-03-07
TWI752086B (zh) 2022-01-11
PH12019500567A1 (en) 2019-11-18

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
CY1125052T1 (el) Κρυσταλλικες μορφες
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
CY1122196T1 (el) Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201790275A1 (ru) Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида